Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma According to Risk Factors: The STAR-TOR Registry
Open Access
- 16 March 2021
- journal article
- research article
- Published by Taylor & Francis in Future Oncology
- Vol. 17 (18) , 2325-2338
Abstract
Aim: Examine outcomes in sunitinib-treated patients by International Metastatic RCC Database Consortium (IMDC) or Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors. Patients & methods: Pa...Keywords
Funding Information
- Pfizer Pharma GmbH
This publication has 42 references indexed in Scilit:
- Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of EfficacyEuropean Urology, 2016
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 2016
- Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapyWorld Journal of Urology, 2016
- SnapShot: Renal Cell CarcinomaCell, 2015
- Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysisScientific Reports, 2015
- Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database ConsortiumClinical Genitourinary Cancer, 2015
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic SettingClinical Cancer Research, 2015
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002